Publications

Primary Peer-Reviewed Publications

  1. Loomba R. Autoimmune hepatitis: a clinical challenge. November 2002, The Resident Reporter Journal, published by AGA.
  2. Loomba R and Liang TJ. Novel approaches to new therapies for hepatitis B virus infection. Antiviral therapy 2006; 1: 1-16.
  3. Lutchman G, Modi A, Pomrat K, Kleiner D, Ghany MG, Heller T, Loomba R, Park Y, Liang TJ, Hoofnagle JH. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007 Aug; 46 (2): 424-9
  4. Loomba R and Ghany MG. Diagnosis and treatment of chronic HBeAg-negative hepatitis B. Current Hepatitis Reports 2007; 6:146-153.
  5. Loomba R and Liang TJ. Treatment of chronic hepatitis B. Antiviral Therapy. 2007; 12 Suppl 3:H33-41.
  6. Loomba R, and Ghany MG. Association of BMI and diabetes and hepatocellular carcinoma. The Annals of Internal Medicine 2008 Jan 15;148 (2):166-7.
  7. Loomba R, Hwang SJ, O’Donnell CJ, Ellison RC, Vasan RS, D’Agostino RB, Liang TJ, and Fox CS. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology 2008 Apr;134 (4):953-9.*
  8. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, and Csako G. Preventive lamivudine reduces the risk of chemotherapy-induced hepatitis B virus reactivation: A systematic review. The Annals of Internal Medicine. 2008 Apr 1;148 (7):519-28.*
  9. Loomba R, Rowley A, Wesley R, Smith K, Liang TJ, Pucino F, and Csako G. Hepatitis B immunoglobulin and lamivudine reduce hepatitis B related morbidity and mortality post-liver transplantation: Meta-analysis. Clin Gastroenterol Hepatol. 2008 June. 6(6):696-700*
  10. Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE and Lavine JE. Placebo in Nonalcoholic Steatohepatitis: Insight into Natural History and Implications for Future Clinical Trials. Clin Gastroenterol Hepatol. 2008 Nov;6(11):1243-8*
  11. Loomba R, Lutchman GA, Kleiner D, Feld J, Borg B, Modi A, Premkumar A, Sumner A, Liang TJ, and Hoofnagle JH. Clinical Trial: A pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2009; 29(2): 172-182
  12. Loomba R, Kleiner DE, and Hoofnagle JH. Mechanism of action of metformin in nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2009; 29 (5): 603-604
  13. Stein L and Loomba R. Drug targets for hepatitis B virus. Infectious Disorders- Drug Targets. 2009 Mar;9(2):105-16
  14. Loomba R, Wesley B, Bain A, Csako G, Pucino F. Role of flouroquinolones in primary prophylaxis of spontaneous bacterial peritonitis: Meta-analysis. Clinical Gastroenterology and Hepatology. 2009 Apr;7(4):487-93 
  15. Loomba R, Sirlin CB, Schwimmer JB and Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009 Oct; 50(4):1282-93
  16. Palmore TN, Shah NL, Loomba R, Borg BB, Lopatin U, Feld JJ, Khokar F, Lutchman G, Kleiner DE, Young N, Childs R, Barrett JA, Liang TJ, Hoofnagle JH, Heller T. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immune suppression. Clinical Gastroenterology and Hepatology. 2009 Oct;7(10):1130-7
  17. Loomba R, Bettencourt R, and Barrett-Connor E. Synergistic association between alcohol intake and body mass index with serum alanine and aspartate aminotransferase levels in older adults: The Rancho Bernardo Study. Alimentary Pharmacology and Therapeutics. 2009 Dec 1;30 (11-12):1137-49.
  18. Stein LS, Dong MH, and Loomba R. Insulin Sensitizers in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Current Status. Advances in Therapy. 2009 Oct;26(10):893-907.
  19. Rotman Y, Borg BB, Soza A, Feld JJ, Modi AA, Loomba R, Lutchman G, Rivera E, Doo E, Ghany MG, Heller T, Neumann AU, Liang TJ, Hoofnagle JH. Clinical trial: low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3 - efficacy, tolerability, viral kinetics and cytokine response. Aliment Pharmacol Ther. 2010 May;31(9):1018-27.
  20. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010 May 6;362(18):1675-85.
  21. Loomba R, Rao F, Zhang L, Khandrika S, Ziegler M, Brenner DA, and O’Connor DT. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology. 2010 Sep;139(3):836-45
  22. Loomba R, Yang YI, Su J, Brenner DA, Iloeje U, and Chen CJ. Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men. Clin Gastroenterol Hepatol. 2010 Oct;8(10):891-8, 898.e1-2.
  23. Chalasani NP, Guo X, Loomba R, Mark GO, Haritunians T, Kwon S, Jinrui C, Kent TD, Wilson L; Cummings WO, Chen IY, and Rotter JI. Genome-wide association scan (GWAS) of patients with histologically characterized nonalcoholic fatty liver disease (NAFLD). Gastroenterology 2010 Nov;139(5):1567-76, 1576
  24. Dong M, Bettencourt R, Barrett-Connor EB, and Loomba R. Alanine Aminotransferase decreases with age: The Rancho Bernardo Study. PLoS One. 2010 Dec 8;5(12):e14254
  25. Loomba R, McBurney R, Vanessa-Williams, Park Y, Barbara Rehermann, Alter H, Liang TJ, Hoofnagle JH and Heller T. Acute hepatitis C: Clinical presentation, laboratory findings, and treatment outcomes. Alimentary Pharmacology and Therapeutics. 2011 Mar;33(5):559-65
  26. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011 Mar;53(3):810-20
  27. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.  JAMA. 2011 Apr 27;305(16):1659-68
  28. Wassel CL, Loomba R, Ix JH, Allison MA, Denenberg JO, Criqui MH. Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease the San Diego population study. J Am Coll Cardiol. 2011 Sep 20;58(13):1386-92
  29. Dong M, Bettencourt R, Brenner DA, Barrett-Connor EB, and Loomba R. Serum Levels of Alanine Aminotransferase Decrease with Age in Longitudinal Analysis. Clinical Gastroenterology and Hepatology (in press)
  30. Boettcher E, Csako G, Pucino F, Wesley R, and Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics (in press)
  31. Lee JK, Bettencourt R, Brenner DA, Le TA, Barrett-Connor E , and Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: The Rancho Bernardo Study. PLoS One. 2012;7(4):e34218.
  32.  Le TA, Chen J, Changchien C, Peterson M, Kono Y, Patton H, Cohen BL, Brenner DA, Sirlin C and Loomba R for the San Diego NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trialACCEPTED in Hepatology
  33.  Loomba R, Yang YI, Iloeje U, Jun Su, Brenner DA, Barrett-Connor E and Chen CJ. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study. ACCEPTED in American Journal of Epidemiology
  34.  Loomba R, Abraham MB, Unalp A, Wilson L, Lavine JE, Doo E, Bass M, and the NASH Clinical Research Network. Association between diabetes, family history of diabetes and risk of nonalcoholic steatohepatitis and fibrosis. ACCEPTED in Hepatology.
  35.  Loomba R. Who should undergo a liver biopsy in NAFLD? AGA Perspectives 2012, June issue (invited review, in peer-review).
  36. Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, Unalp-Arida A, Bass N;Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012; 55(3):769-80. doi: 10.1002/hep.24726.
  37. Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012 May 3. [Epub ahead of print]
  38. Le TA, Loomba R. Management of nonalcoholic fatty liver disease and steatohepatitis. Accepted for publication in Journal of Clinical and Experimental Hepatology
  39. Noureddin M, and Loomba R. Indications for liver biopsy & Non-invasive biomarkers in nonalcoholic fatty liver disease. Accepted for publication in Clinical Liver Disease.
  40. Abecassis M, Bridges ND, Clancy CJ, Dew MA, Eldadah B, Englesbe MJ, Flessner MF, Frank JC, Friedewald J, Gill J, Gries C, Halter JB, Hartmann EL, Hazzard WR, Horne FM, Hosenpud J, Jacobson JP, Kasiske BL, Lake J, Loomba R, Malani PN, T.M. Moore TM, Murray A, Nguyen M-H, Powe NR, Reese PP, Reynolds H, Samaniego MD, Schmader KE, Segev DL, Shah AS, Singer LG, Sosa JA, Stewart ZA, Tan JC, Williams WW, Zaas DW, High KP. Solid Organ Transplantation in Older Adults: Current Status and Future Research. Accepted for publication in American Journal of Transplantation.
  41. Rose SC, Kikolski SG, Gish RG, Kono Y, Loomba R, Hemming AW, Wallace MJ; On behalf of the Society of Interventional Radiology. Society of interventional radiology critique and commentary on the Cochrane report on transarterial (chemo)embolization. Hepatology. 2013 Apr;57(4):1675-6
  42. Hwang JP, Vierling JM, Zelenetz AD, Lackey SC, Loomba R. Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012 Nov;20(11):2999-3008
  43. Zarrinpar A and Loomba R. Systematic Review: The Emerging Interplay Between Bile Acids, Gastrointestinal Tract, and Incretins in the Pathogenesis of Diabetes and Nonalcoholic Fatty Liver Disease. Aliment Pharmacol Ther. 2012 Nov;36(10):909-21
  44. Loomba R, Doycheva I, Bettencourt R, Cohen B, Wassel C, Brenner DA, and Barrett-Connor E. Serum gamm-glutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults. Accepted for publication in Journal of Clinical and Experimental Hepatology.
  45. Doycheva I, Patel N, Peterson M, Loomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. J Diabetes Complications. 2013 May-Jun;27(3):293-300
  46. Patel N, Peterson MR, Brenner DA, Heba E, Sirlin C, Loomba R. Association between novel MRI-estimated pancreatic fat and liver histology-determined steatosis and fibrosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2013 Mar;37(6):630-9.
  47. Patel NS, Loomba R. Commentary: non-alcoholic fatty pancreas -- toward an uncharted territory; authors' reply. Aliment Pharmacol Ther. 2013 May;37(9):916-7
  48. Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis. Radiology. 2013 May;267(2):422-431
  49. Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, Seki E. Transforming Growth Factor-β Signaling in Hepatocytes Promotes Hepatic Fibrosis and Carcinogenesis in Mice with Hepatocyte-Specific Deletion of TAK1. Gastroenterology. 2013 May;144(5):1042-1054.
  50. Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Tonascia J; the Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN). Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013 Jul;38(2):134-43.
  51. Jensky NE, Allison MA, Loomba R, Carnethon MR, de Boer IH, Budoff MJ, Burke GL, Criqui MH, Ix JH. Null association between abdominal muscle and calcified atherosclerosis in community-living persons without clinical cardiovascular disease: The multi-ethnic study of atherosclerosis. Metabolism. 2013 Nov;62(11):1562-9
  52. Loomba R and Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90 
  53. Patel NS*, Peterson MR, Lin GY, Feldstein A, Schnabl A, Bettencourt R, Seki E, Sirlin CB, and Loomba R. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterol Res Pract. 2013;2013:498296
  54. Noureddin M*, Yates KP, Vaughn IA, Neuschwander-Tetri BA, Sanyal AJ, McCullough A, Merriman R, Hameed B,  Doo E, Kleiner DE, Behling C, and Loomba R for the NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013.Nov; 58 (5):1644-54
  55. Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ. Synergistic Effects of Family History of Hepatocellular Carcinoma and Hepatitis B Virus Infection on Risk for Incident Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2013 Dec;11(12):1636-1645.
  56. Noureddin M*, Lam J, Peterson M, Middleton M, Hamilton G, Le TA, Changchien C, David A. Brenner DA, Sirlin C, and Loomba R. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013 Dec;58(6):1930-40.
  57. Doycheva I* and Loomba R. Effect of metformin on ballooning degeneration in NASH: When to use metformin in NAFLD. Adv. Ther. 2014 Jan;31(1):30-43
  58. Johnson BL, Schroeder ME, Wolfson T, Gamst AC, Hamilton G, Shiehmorteza M, Loomba R, Schwimmer JB, Reeder S, Middleton MS, Sirlin CB. Effect of flip angle on the accuracy and repeatability of hepatic proton density fat fraction estimation by complex data-based, T1-independent, T2*-corrected, spectrum-modeled MRI. J Magn Reson Imaging. 2014 Feb; 39(2):440-7
  59. Yang L, Roh YS, Song J, Zhang B, Liu C, Loomba R, Seki E. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology. 2014 Feb;59(2):483-95
  60. Stinton L* and Loomba R. Recommendations for liver biopsy evaluation in nonalcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2014 Mar;60(1):5-13
  61. Levin YS, Yokoo T, Wolfson T, Gamst AC, Collins J, Achmad EA, Hamilton G, Middleton MS, Loomba R, Sirlin CB. Effect of echo-sampling strategy on the accuracy of out-of-phase and in-phase multiecho gradient-Echo MRI hepatic fat fraction estimation. J Magn Reson Imaging. 2014 Mar;39(3):567-75
  62. Boland BS*, Dong MH*, Bettencourt R, Barrett-Connor E, and Loomba R. Association of serum bilirubin with aging and mortality. J Clin Exp Hepatol 2014;4:1–7
  63. Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterol Hepatol. 2014 Apr;10(4):219-27.
  64. Negrete LM, Middleton MS, Clark L, Wolfson T, Gamst AC, Lam J, Changchien C, Deyoung-Dominguez IM, Hamilton G, Loomba R, Schwimmer J, Sirlin CB. Inter-examination precision of magnitude-based MRI for estimation of segmental hepatic proton density fat fraction in obese subjects. J Magn Reson Imaging. 2014 May;39(5):1265-71
  65. Pearlman M* and Loomba R. State of the art: Treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2014 May;30(3):223-37
  66. Bonekamp S, Tang A, Mashhood A, Wolfson T, Changchien C, Middleton MS, Clark L, Gamst A, Loomba R, Sirlin CB. Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging. 2014 Jun;39(6):1525-32
  67. Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular Carcinoma Surveillance: A National Survey of Current Practices in the USA. In press Dig Dis Sc 2014
  68. Bambha K ,Wilson LA, Unalp A, Loomba R, Neuschwander-Tetri BA, Brunt EM, Bass NM for the NASH CRN. Coffee Consumption in NAFLD Patients with Lower Insulin Resistance is Associated with Lower Risk of Severe Fibrosis. In press Liver International 2013.
  69. Singh S*, Allen AM*, Wang Z, Prokop LJ, Murad MH, and Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. In press Clin Gastroenterol Hepatol.2014
  70. Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults with Nonalcoholic Fatty Liver Disease. In press Clin Gastroenterol Hepatol.2014
  71. Loomba R, Wolfson T, Ang B, Booker J, Behling C, Peterson M, Valasek M, Lin G, Brenner D, Gamst A, Ehman R, Sirlin C. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology 2014 Dec;60(6):1920-8
  72. Loomba R. Rationale for conducting randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: Pleiotropic effects hypothesis. Hepatology 2014 Dec;60(6):1818-22
  73. Chen P, Torralba M, Tan J, Embree M, Zengler K, Stärkel P, Pijkeren JP, DePew J, Loomba R, Ho SB, Bajaj JS, Mutlu EA, Keshavarzian A, Tsukamoto H, Nelson KE, Fouts DE, Schnabl B. Supplementation of Saturated Long-chain Fatty Acids Maintains Intestinal Eubiosis and Reduces Ethanol-induced Liver Injury in Mice. Gastroenterology. 2015 Jan;148(1):203-214.
  74. Roh YS, Loomba R, Seki E. The TM6SF2 Variants, Novel Genetic Predictors for Nonalcoholic Steatohepatitis. Gastroenterology 2015 Jan;148(1):252-4
  75. Loomba R, Quehenberger O, Amado A, Dennis EA. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. Journal of Lipid Research 2015 Jan;56(1):185-92.
  76. Tang A, Chen J, Le TA*, Changchien C, Hamilton G, Middleton MS, Loomba R, Sirlin CB. Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis. In press Abdom Imaging 2015
  77. Singh S*, Allen AM*, Wang Z, Prokop LJ, Murad MH, and Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. In press Clin Gastroenterol Hepatol.2015
  78. Patel NS, Doycheva I, Peterson MR, Hooker J, Kisselva T, Schnabl B, Seki E, Sirlin CB, and Loomba R. Effect of Weight Loss on MRI Estimation of Liver Fat and Volume in Patients With Nonalcoholic Steatohepatitis. In press Clinical Gastroenterology and Hepatology 2015
  79. Spengler EKJ*, Loomba R. Gut microbiome, Intestinal permeability, bacterial translocation and NAFLD. In press Cellular and Molecular Gastroenterology and Hepatology 2015
  80. Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR Imaging-estimated Proton Density Fat Fraction for Classification of Dichotomized Histologic Steatosis Grades in Nonalcoholic Fatty Liver Disease. In press Radiology. 2015.
  81. Murphy P, Hooker J, Ang B, Wolfson T, Gamst A, Bydder M, Middleton M, Peterson M, Behling C, Loomba R, Sirlin C. Associations between histologic features of nonalcoholic fatty liver disease (NAFLD) and quantitative diffusion-weighted MRI measurements in adults. In press J Magn Reson Imaging. 2015
  82. Vodkin I*, Bettencourt R, Valasek MV, Cachay E, Loomba R.  Clinical, biochemical and histologic differences between HIV-associated NAFLD and primary NAFLD: a case-control study. In press Alimentary Pharmacology and Therapeutics 2015.
  83. Lin SC*,  Heba E, Wolfson T, Ang B, Gamst A, Han A,  Erdman Jr. JW, O’Brien Jr. WD, Andre MP, Sirlin CB, and Loomba R. Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat by new quantitative ultrasound. In press Clinical Gastroenterology and Hepatology 2015.
  84. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. Farsenoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. In press Lancet 2015
  85. Loomba R, Sirlin C, Ang B, Bettencourt R, Jain R*, Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M*, Haufe W, Hooker C, Yin M, Ehman R, Lin G, Valasek M, Brenner D, Richards L. Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel MRI and MRE in a randomized trial (MOZART Trial). In press Hepatology 2015.
  86. Arulanandan A*, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, Valasek MA, Ix JH, Schnabl B, Sirlin CB, Loomba R. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients with Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. In press Clinical Gastroenterology and Hepatology 2015
  87.  Cui J*, Ang B, Haufe W, Hernandez C, Verna EC, Sirlin CB, Loomba R. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther. 2015 Jun;41(12):1271-80
  88.  Arulanandan A. Loomba R. Noninvasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Current Hepatology Reports. 2015(14); 109-18
  89.  Bazick J*, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015 Jul;38(7):1347-55
  90. Wanner A, Groft SC, Teagarden JR, Krischer J, Davis BR, Coffey CS, Hickam, Teckman J, Nelson DR, McCaleb M, Loomba R, Strange C, Sandhaus RA, Brantly M, Edelman JM, Farrugia A. Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. Journal of COPD Foundation. 2015;2(2): 177-190
  91.  Roh YS, Zhang B, Loomba R, Seki E. TLR2 and TLR9 contribute to alcohol-mediated liver injury through induction of CXCL1 and neutrophil infiltration. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 1;309(1):G30-41
  92.  Verna EC, Patel J, Bettencourt R, Nguyen P, Hernandez C, Valasek MA, Kisselva T, Brenner DA, Loomba R. Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2015 Sep;42(5):582-90
  93.  Halldorson J, Kazi Z, Mekeel K, Kuo A, Hassanein T, Loomba R, Austin S, Valasek MA,Kishnani P, Hemming AW. Successful combined liver/kidney transplantation from a donor with Pompe disease. Mol Genet Metab. 2015 Aug;115(4):141-4
  94.  Spengler E*, Loomba R. Recommendations for Diagnosis, Referral for Liver Biopsy and Treatment of NAFLD and NASH. In press Mayo Clinic Proceedings 2015
  95. Hamilton G, Middleton MS, Hooker JC, Haufe WM, Forbang NI, Allison MA, Loomba R, Sirlin CB. In vivo breath-hold 1 H MRS simultaneous estimation of liver proton density fat fraction, and T1 and T2 of water and fat, with a multi-TR, multi-TE sequence. In press J Magn Reson Imaging. 2015
  96.  Singh S*, Murad MH, Chandar AK, Bongiorno CM, Singal AK, Atkinson SR, Thursz MR, Loomba R, Shah VH. Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. In press Gastroenterology 2015
  97.  Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh P, Flaherty JF, Martins EB,Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015 [Epub ahead of print]
  98.  Singh S*, Khera R, Wang Z, Prokop LJ, Murad MH, and Loomba R. Comparative Effectiveness of Pharmacological Interventions for Non-alcoholic Steatohepatitis: A Systematic Review and Network Meta-analysis. Hepatology. 2015 [Epub ahead of print]
  99.  Singh S*, Venkatesh SK, Loomba R, Wang Z, Sirlin C, Chen J, Yin M, Miller FH, Low RN,Hassanein T, Godfrey EM, Asbach P, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Euro. Radiology. 2015 [Epub ahead of print]
  100.  Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, Ang B, Nguyen P, Hernandez C, Richards L, Salotti J, Lin S*, Seki E, Nelson KE, Sirlin CB, Brenner D; Genetics of NAFLD in Twins Consortium. Gastroenterology. 2015 [Epub ahead of print]
  101.  Mencin AA, Loomba R, Lavine JE. Caring for the children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol. 2015 [Epub ahead of print]
  102. Tyagi A, Yeganeh O, Levin Y, Hooker JC, Hamilton GC, Wolfson T, Gamst A, Zand AK, Heba E, Loomba R, Schwimmer J, Middleton MS, Sirlin CB. Intra- and inter-examination repeatability of magnetic resonance spectroscopy, magnitude-based MRI, and complex-based MRI for estimation of hepatic proton density fat fraction in overweight and obese children and adults. Abdominal Imaging 2015 [Epub ahead of print]
  103.  Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015 [Epub ahead of print]

Editorials

  1. Stinton L*, Loomba R. Dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet. Aliment Pharmacol Ther. 2014 Apr;39(8):894-5
  2. Loomba R. Serum alanine aminotransferase as a biomarker of treatment response in nonalcoholic steatohepatitis. In press Clin Gastroenterol Hepatol.2014
  3. Loomba R. Rationale for conducting randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: Pleiotropic effects hypothesis. In press Hepatology 2014
  4.  Roh YS, Loomba R, Seki E. The TM6SF2 Variants, Novel Genetic Predictors for Nonalcoholic  Steatohepatitis. Gastroenterology 2015 Jan;148(1):252-4
  5.  Spengler EKJ*, Loomba R. Gut microbiome, Intestinal permeability, bacterial translocation and NAFLD. In press Cellular and Molecular Gastroenterology and Hepatology 2015
  6.  Verna EC, Loomba R. Call to screen for NAFLD and NASH in psoriasis. Aliment Pharmacol Ther. 2015 Mar;41(5):492-3
  7.  Loomba R, Cortez-Pinto H. Exercise and improvement of NAFLD: Practical recommendations. J Hepatol. 2015 Jul;63(1):10-2.
  8.  Loomba R, Cortez-Pinto H. Exercise and improvement of NAFLD: Practical recommendations. J Hepatol. 2015 Jul;63(1):10-2.
  9.  Loomba R, Cortez-Pinto H. Exercise and improvement of NAFLD: Practical recommendations. J Hepatol. 2015 Jul;63(1):10-2.
  10.  Loomba R, Chalasani N. The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH. Gastroenterology. 2015 Aug;149(2):278-81

Oral and Abstract Presentations

  1.   Loomba R and Marshall JP, St. Luke’s Hospital, St. Louis. Mesocaval shunt graft migration through the bowel wall and passing through the ileostomy. Poster presentation at ACG meeting at Seattle, Oct. 2002.
  2.  Loomba R, Brunt EM, Luxon BA, Bacon BR, and Neushwander-Tetri BA. Long-term outcome of patients with autoimmune hepatitis with high or low dose prednisone as initial therapy is equal. Oral presentation in DDW, May 2002. Gastroenterology (Abstract) 2002; 122:A-628: 109
  3.  Feld J, Gladwin M, Kleiner D, Loomba R, Liang TJ, Hoofnagle JH and Heller T. Liver Diseases Branch, NIDDK NIH. Liver disease in sickle cell anemia. Poster presentation at AASLD, 2005.
  4. Borg B, Neumann A, Ghany M, Heller T, Kleiner D, Loomba R, Liang TJ and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Trial of low dose peginterferon alfa-2a and ribavirin for patients with chronic hepatitis C infected with genotype 2 or 3. Poster presentation at AASLD, 2005.
  5. Lutchman G, Neumann A, Ghany M, Heller T, Loomba R, Liang TJ and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Early viral kinetics in patients with chronic hepatitis C and end stage renal disease during therapy with Peginterferon alpha-2a. Poster presentation at AASLD, 2005.
  6. Ghany M, Lutchman G, Kleiner D, Borg B, Heller T, Loomba R, Liang TJ, and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Lamivudine and Adefovir versus Adefovir alone for HbeAg-positive chronic hepatitis B. Poster presentation at AASLD, 2005.
  7. Loomba R and Heller T. Liver Diseases Branch, NIDDK, NIH. Prospective study of liver involvement in Turner Syndrome: elevation in liver enzymes and their relation with syndrome specific features. Poster presentation at NIDDK Fellows Retreat, 2005.
  8. Loomba R, Lutchman G, Kleiner D, Heller T, Ghany M, Liang TJ and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Histologic changes in nonalcoholic steatohepatitis in untreated patients: a paired liver biopsy study. Poster presentation in NASH clinical research forum in DDW, 2005.
  9. Loomba R, McBurney R, Lutchman GA, Rehermann B, Herrine SK, Alter H, Liang TJ, Hoofnagle JH and Heller T. Liver Diseases Branch, NIDDK, NIH. Acute hepatitis C: clinical presentation, laboratory findings, and treatment outcomes. Oral presentation at AASLD, 2005.
  10. Loomba R, Lutchman GA, Kleiner D, Feld J, Borg B, Ghany M, Heller T, Doo E, Modi A, Liang TJ, and Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH. Metformin for the treatment of nonalcoholic steatohepatitis. Oral presentation at AASLD 2006.
  11. Feld JJ, Lutchman GA, Loomba R, Ghany M, Heller T, Liang TJ,  Neumann A, Hoofnagle JH. Liver Diseases Branch, NIDDK, NIH, Bethesda, MD. Should peginterferon be dosed twice weekly? Poster presentation at AASLD meetings 2007.
  12. Rotman Y, Borg B, Soza A, Loomba R, Modi AA, Feld JJ, Rivera E, Doo E, Heller T, Ghany MG, Liang TJ, Hoofnagle JH.  Liver Diseases Branch, NIDDK, NIH, Bethesda, MD. Low dose peginterferon alfa-2a and ribavirin for chronic hepatitis C, genotype 2 & 3: viral kinetics, efficacy and safety. Poster presentation at AASL meetings 2007.
  13. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, and Csako G. Liver Diseases Branch, NIDDK, NIH, Bethesda, MD. Pre-emptive lamivudine reduces the risk of chemotherapy-induced HBV-related morbidity and mortality in HBsAg positive cancer patients: A Meta-analysis. Poster presentation at AASLD meetings 2007.
  14. Loomba R, Rowley A, Wesley R, Smith K, Liang TJ, Pucino  F, and Csako  G. Hepatitis B immunoglobulin and lamivudine reduce hepatitis B related morbidity and mortality post-liver transplantation: Meta-analysis. Poster presentation at DDW meetings 2008.
  15. Loomba R, Bettencourt R, and Barrett-Connor E. Sex-specific association between alcohol intake, body size and serum aminotransferase levels: The Rancho Bernardo Study. Poster presentation at AASLD meetings 2008.
  16. Loomba R, Bettencourt R, Brenner D and Barrett-Connor E. Serum γ-glutamyl transpeptidase independently predicts mortality in older adults: The Rancho Bernardo Study. Poster presentation at DDW meetings 2009.
  17. Loomba R, Yang YI, Su J, Brenner DA, Iloeje U, and Chen CJ. Synergistic effect of obesity and alcohol on risk of hepatocellular carcinoma in men: a prospective cohort study. Poster presentation at AASLD meetings 2009.
  18. Loomba R, Rao F, Zhang L, Khandrika S, Ziegler M, Brenner DA, and O’Connor DT. Genetic covariance between gamma-glutamyl transpeptidase (GGT) and fatty liver risk factors, as well as the novel effect of 2-adrenergic receptor (ADRB2) genetic variation: A twin study.  Poster presentation at AASLD meetings 2009.
  19. Loomba R, Yang YI, Su J, Brenner DA, Barrett-Connor E, and Chen CJ. Synergistic effect of obesity and alcohol on risk of hepatocellular carcinoma: a prospective cohort study. Poster presentation at DDW meetings 2010.
  20. Dong M, Bettencourt R, Barrett-Connor E, and Loomba R. Alanine aminotransferase decreases with age: The Rancho Bernardo Study. Oral presentation at DDW 2010.
  21. Loomba R, Neuschwander-Tetri BA, Sanyal AJ, Chalasani NC, Kowdley K, McCullough AJ, Diehl AM, Bass NM,  Lavine JE, Brunt EM, Kleiner D, Donithan M, Van Natta M, Tonascia J, Unalp A, Clark JM, and Robuck PR for the NASH CRN. Changes in ALT and vitamin E levels and histological response in patients with NASH treated with vitamin E in the PIVENS trial.  Poster presentation at AASLD 2010.
  22. Boland B, Bettencourt R, Brenner DA, Barrett-Connor E, and Loomba R. Association between serum bilirubin and mortality in older adults: The Rancho Bernardo Study. Poster presentation at DDW 2011.
  23. Loomba R, Abraham M, Unalp A, Wilson L,  Lavine J, Doo E, Bass NM. and the NASH Clinical Research Network. Association between family history of diabetes and risk of nonalcoholic steatohepatitis. Poster presentation at DDW 2011.
  24. Noureddin M, Vaughn I, Neuschwander-Tetri BA, Sanyal AJ, McCullough AJ, Merriman R, Yates K, Tonascia J, Ünalp-Arida A, Doo E, Kleiner DE, Behling C, and Loomba R and the NASH CRN. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in the elderly. Poster presentation at AASLD 2011.
  25. Le TA, Chen J, Changchien C, Peterson M, Kono Y, Patton H, Cohen BL, Brenner DA, Sirlin C and Loomba R for the San Diego NAFLD Research Consortium (SINC). Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: A randomized controlled trial”. Poster presentation at DDW 2012.
  26. Permutt Z, Le TA, Peterson M, Seki E, Brenner DA, Sirlin C and Loomba R. Correlation between liver histology and novel magnetic resonance imaging in adult patients with nonalcoholic fatty liver disease. Poster presentation at DDW 2012.
  27. Tang A, Chen J, Le TA, Changchien C, Hamilton G, Middleton MS, Sirlin CB, and Loomba R. Novel assessment of total liver fat index and liver volume using magnetic resonance imaging in patients with nonalcoholic fatty liver disease. Poster presentation at AASLD 2012.
  28. Bambha K, Wilson L, Unalp A, Loomba R, Neuschwander-Tetri B, Brunt EM, and Bass NM. Coffee Consumption in NAFLD Patients with Lower Insulin Resistance is Associated with Lower Risk of Severe Fibrosis. Poster presentation at AASLD 2012.
  29. Loomba R, Liu J, Yang HI, Brenner D, and Chen CJ. Synergistic interaction between family history of hepatocellular carcinoma and hepatitis B virus infection in increasing the risk of incident hepatocellular carcinoma. Poster presentation at AASLD 2012.
  30. Noureddin M, Le TA, Peterson MR, Middleton MS, Hamilton G, Changchien C, Brenner D, Sirlin CB, and Loomba R. Liver fat quantification using novel magnetic resonance imaging (MRI) technique correlates robustly with MR spectroscopy and histology: A longitudinal study with repeat measures in patients with nonalcoholic fatty liver disease. Poster presentation at AASLD 2012.
  31. Liu S, Bettencourt R, Schlang AM, Fehmi SAM, Brenner D, Sirlin CB, Barrett-Connor E, and Loomba R. Novel effect of aging shows decline in fatty liver despite increase in visceral fat: A prospective population-based cohort study. Poster presentation at AASLD 2012.
  32. Kohli R, Dodd CN, Loomba R, Fenchel M, Belt PH, Yeh MM, Rosenthal P, Sanyal AJ, and Xanthakos S. High Serum Alpha-1-Antitrypsin Levels are Associated with More Fibrosis in NASH. Poster presentation at AASLD 2012.
  33. Lavine JE, Yates KP, Brunt EM, Kleiner DE, Schwimmer JB, Murray KF, Molleston JP, Abrams SH, Rosenthal P, Loomba R, Unalp A, and Tonascia J. The natural history of nonalcoholic fatty liver disease in children and adolescents assessed in placebo recipients in the TONIC trial. Poster presentation at AASLD 2012.
  34. Tang A, Szeverenyi NM, Cunha GM, Lam J, Loomba R, Ehman RL, MD Sirlin C. Liver MR Elastography: A Primer for Radiologists. Education Exhibits (Abstract ID 12022950). RSNA Chicago November 2012. Awarded Magna Cum Laude Award.
  35. Loomba R, Lam J, Wolfson T, Ang B, Bhatt A, Peterson MR, Brenner DA, and Sirlin C. Magnetic Resonance Elastography Accurately Predicts Advanced Fibrosis in NAFLD: A Pilot Study with Paired-Liver Biopsy. Poster presentation at DDW 2013.
  36. Vuppalanchi R, Deppe RB, Yates KP, Comerford M, Masuoka HC, Tetri BA, Loomba R, Brunt E, Kleiner DE, Tonascia J, and Chalasani NP. Changes in Serum Cytokeratin 18 Levels Significantly Predict Changes in Liver Histology in Adults With Nonalcoholic Steatohepatitis: Results from the PIVENS Trial. Poster presentation at DDW 2013.
  37. Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen YD, Goodarzi MO, Taylor KD, Yates KP, Unalp A, and Rotter JI. Novel Genetic Loci Associated With Steatohepatitis and Fibrosis in Hispanic Boys With Nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2013.
  38. Doycheva I, Noureddin M, Patel NS, Peterson MR, Brenner DA, Sirlin C, and Loomba R. Effect of Weight Loss on Novel MRI Quantitative Changes in Liver and Pancreatic Fat in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Poster presentation at DDW 2013.
  39. Desai A, Tang A, Wolfson T, Peterson M, Clark L, Loomba R, Middleton M, Sirlin C. Accuracy of magnetic resonance imaging (MRI) estimated proton density fat fraction (PDFF) thresholds for diagnosis of histology determined steatosis grades in adults with non-alcoholic fatty liver disease. ARRS Washington DC 2013.
  40. Joshi K, Ang B, Gish R, Loomba R, Kuo A, Patton H, Kono Y, and UCSD Medicine. Hepatocellular Carcinoma Surveillance: An Inquiry Into Current Practices. Poster presentation at ILCA 2013.
  41. Samala N, May KP, Kleiner DE, and Loomba R. Normal Weight Nonalcoholic Steatohepatitis (NASH). Poster presentation at AASLD 2013.
  42. Loomba R, Alturki A, Han A, Lam J, Ang B, Bhatt A, Hooker J, Shah A, Zand K, Middleton MS, Wolfson T, O'Brien WD, Sirlin CB, and Andre MP. Novel quantification of liver fat by ultrasound backscatter technique & its correlation with MRI-estimated proton density fat fraction in NAFLD vs healthy controls. Poster presentation at AASLD 2013.
  43. Patel N, Peterson MR, Lin GY, Bettencourt R, Sirlin CB, and Loomba R. MRI-estimated pancreatic fat is associated with insulin resistance and is greater in patients with non-alcoholic fatty liver disease than healthy controls. Poster presentation at AASLD 2013.
  44. Heba E, Desai A, Wolfson T, Chavez T, Lam JC, Hooker J, Clark LG, Loomba R, Gamst A, Sirlin CB, Middleton MS. Correlation Between MRI- and MRS-estimated Proton Density Fat Fraction (PDFF) in 506 Adult Subjects with Non-alcoholic Fatty Liver Disease (NAFLD). (RSNA Abstract ID # 13020771) Poster presentation at RSNA, Chicago, 2013.
  45. Alturki AT, Han A, Lam J, Hooker JC, Shah A, Zand KA, Middleton MS, O’Brien WD, Loomba R, Sirlin CB. Correlation of Quantitative Ultrasound Backscatter with 3T MRI-estimated Proton Density Fat Fraction (PDFF) for Assessment of Hepatic Steatosis. (RSNA Abstract ID # 13020530) Scientific Formal Paper presentation at RSNA, Chicago, 2013.
  46. Loomba R, Wolfsen T, Haufe W, Hooker J, Szeverneyi N, Ang B, Peterson M, Valasek  M, Lin G, Gamst A, Brenner DA, Sirlin CB. Novel 3-dimensional magnetic resonance elastography accurately diagnoses nonalcoholic steatohepatitis and advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective cohort study. Oral presentation at EASL, London, 2014.
  47. Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon S, Janssen H, Lampertico P, Lau D, Bornstein J, Schall RA, Dinh P, Yee LJ, Martins EB, Lim SG, Loomba R, Petersen J and Marcellin P. APRI and FIB-4 vs histology in chronic hepatitis B patients in tenofovir disoproxil fumarate trials. Poster presentation at EASL, London, 2014
  48. Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine JE, and Loomba R for the NASH CRN. Clinical model for predicting NASH or advanced fibrosis in patients with diabetes and NAFLD. Poster presentation at DDW, Chicago, 2014.
  49. Singh S, Allen AA, Wang Z, Prokop LJ, Murad MH and Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver Versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies. Poster presentation at DDW, Chicago, 2014.
  50. Chang M, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine JE, and Loomba R for the NASH CRN. Patterns in liver histology among normoglycemic,  prediabetic, and diabetic patients with NAFLD. Poster presentation at DDW, Chicago, 2014.
  51. Loomba R, Sirlin C, Ang B, Bettencourt R, Jain R,Salotti J, Soaft L, Hooker J, Kono Y, Bhatt A, Hernandez L, Nguyen P, Noureddin M, Haufe W, Hooker C, Yin M, Ehman R, Lin G, Valasek M, Brenner D, Richards L. Novel MRI and MRE in ezetimibe versus placebo for the treatment of nonalcoholic steatohepatitis: Randomized-controlled trial (MOZART Trial). Poster presentation at AASLD 2014.
  52. Afdhal N, Urban T, Goodman Z, Patel K, Ge D, Guo X, Jiang Z, Zhao X, Paulson M, Gaggar A, Bornstein J, Subramanian M, McHutchison J, Kleinstein S, Long N, Goldstein D, Loomba R, Thompson A. Genome Wide Association Study (GWAS) identifies a SNP near the MRC2 (mannose receptor C, type 2) gene associated with increased liver collagen content in Caucasian HBC patients. Poster presentation at AASLD 2014.
  53. Ray Kim W, Loomba R, Lal P, Schall R, Johnson A, Bornstein J, Subramanian M, McHutchison J, Harrison S, Sanyal A. Serum Lysyl Oxidase Like 2 (sLOXL2) Levels Correlate with Ishak Fibrosis Score and Decrease with Treatment with Tenofovir Disoproxil Fumarate (TDF) in Patients with Chronic Hepatitis B (CHB). Poster presentation at AASLD 2014.
  54. Loomba R, Wolfson T, Haufe W, Hooker J, Szeverenyi N, Ang B, Bhatt A, Behling C, Brenner D, Yin M, Ehman R, Sirlin C. Comparison of 2-dimensional and 3-dimensional magnetic resonance elastography (MRE) for diagnosis of advanced fibrosis in patients with biopsy-proven NAFLD: A prospective study. Poster presentation at AASLD 2014.
  55. Lominadze Z, Harrison S, Charlton M, Loomba R, Neuschwander-Tetri B, Caldwell S, Kowdley K, Rinella M. Survey of Diagnostic and Treatment Patterns of NAFLD and NASH in the United States: Real Life Practices Differ from Published Guidelines. Poster presentation at AASLD 2014.
  56. Vodkin I, Valasek M, Bettencourt R, Cachay E, Loomba R. Clinical and Histologic Differences Between HIV-associated NAFLD and Primary NAFLD: A Case-control Study. Poster presentation at AASLD 2014.
  57. Lin S, Heba E, Wolfson T, Ang B, Gamst A, Han Aiguo, Erdman J, O'Brien W, Andre M, Sirlin C, Loomba R. Diagnosis and Quantification of Fatty Liver with Quantitative Ultrasound using MRI-Derived Proton Density Fat Fraction as Reference in Patients with and without NAFLD. Poster presentation at AASLD 2014.
  58. Jacobs K, Brouha S, Bettencourt R, Sirlin C, Loomba R. Visceral Adiposity but not Hepatic Steatosis is Associated with Coronary Artery Calcification: a Prospective Cohort Study. Poster presentation at AASLD 2014.
  59. Desai A, Bettencourt R, Loomba R. Variation in Liver Disease Related Mortality in the United States. Poster presentation at AASLD 2014.

Access to PubMed: Dr. Rohit Loomba